Cargando…
Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report
BACKGROUND: Clinically, elderly patients with unresectable bulky hepatocellular carcinoma (HCC) are difficult to manage, especially in those with co-infections of hepatitis B and C virus. Herein, we reported such a case treated with radiotherapy (RT) by using combined simultaneously integrated inner...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400349/ https://www.ncbi.nlm.nih.gov/pubmed/27559982 http://dx.doi.org/10.1097/MD.0000000000004717 |
_version_ | 1783230818789883904 |
---|---|
author | Lin, Young-Hsiang Hung, Shih-Kai Chiou, Wen-Yen Lee, Moon-Sing Shen MD, Bing-Jie Chen, Liang-Cheng Liu, Dai-Wei Tsai, Wei-Ta Lin, Po-Hao Shih, Yi-Ting Hsu, Feng-Chun Tsai, Shiang-Jiun Chan, Michael W.Y. Lin, Hon-Yi |
author_facet | Lin, Young-Hsiang Hung, Shih-Kai Chiou, Wen-Yen Lee, Moon-Sing Shen MD, Bing-Jie Chen, Liang-Cheng Liu, Dai-Wei Tsai, Wei-Ta Lin, Po-Hao Shih, Yi-Ting Hsu, Feng-Chun Tsai, Shiang-Jiun Chan, Michael W.Y. Lin, Hon-Yi |
author_sort | Lin, Young-Hsiang |
collection | PubMed |
description | BACKGROUND: Clinically, elderly patients with unresectable bulky hepatocellular carcinoma (HCC) are difficult to manage, especially in those with co-infections of hepatitis B and C virus. Herein, we reported such a case treated with radiotherapy (RT) by using combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy (SIEB-VMAT). After RT, significant symptoms alleviation and durable tumor control were observed. CASE SUMMARY: At presentation, an 85-year-old male patient complained abdominal distention/pain, poor appetite, and swelling over bilateral lower limbs for 1 month. On physical examination, a jaundice pattern was noted. Laboratory studies showed impaired liver and renal function. Abdominal computed tomography (CT) revealed a 12.5-cm bulky tumor over the caudate lobe of the liver. Biopsy was done, and hepatocellular carcinoma (HCC) was reported histopathologically. As a result, AJCC stage IIIA (cT3aN0M0) and BCLC stage C were classified. Surgery, radiofrequency ablation (RFA), trans-catheter arterial chemoembolization (TACE), and sorafenib were not recommended because of his old age, central bulky tumor, and a bleeding tendency. Thus, RT with SIEB-VMAT technique was given alternatively. RT was delivered in 26 fractions, with dose gradience as follows: 39 Gy on the outer Plan Target Volume (PTV), 52 Gy in the middle PTV, and 57.2 Gy in the inner PTV. Unexpectedly, cyproheptadine (a newly recognized potential anti-HCC agent) was retrospectively found to be prescribed for alleviating skin itching and allergic rhinitis since the last 2 weeks of the RT course (2 mg by mouth Q12h for 24 months). After RT, significant symptoms alleviation and tumor volume reduction were observed for 32 months till multiple bone metastases. Before and after RT, a large tumor volume reduction rate of 88.7% was observed (from 608.4 c.c. to 68.7 c.c.). No severe treatment toxicity was noted during and after RT. The patient died due to aspiration pneumonia with septic shock at 4 months after bone metastases identified. CONCLUSIONS: SIEB-VMAT physically demonstrated double benefits of intratumor dose escalation and extra-tumor dose attenuation. Significant tumor regression and symptoms alleviation were observed in this elderly patient with unresectable bulky HCC. Further prospective randomized trials are encouraged to demarcate effective size of SIEB-VMAT with or without cyproheptadine. |
format | Online Article Text |
id | pubmed-5400349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-54003492017-04-27 Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report Lin, Young-Hsiang Hung, Shih-Kai Chiou, Wen-Yen Lee, Moon-Sing Shen MD, Bing-Jie Chen, Liang-Cheng Liu, Dai-Wei Tsai, Wei-Ta Lin, Po-Hao Shih, Yi-Ting Hsu, Feng-Chun Tsai, Shiang-Jiun Chan, Michael W.Y. Lin, Hon-Yi Medicine (Baltimore) 5700 BACKGROUND: Clinically, elderly patients with unresectable bulky hepatocellular carcinoma (HCC) are difficult to manage, especially in those with co-infections of hepatitis B and C virus. Herein, we reported such a case treated with radiotherapy (RT) by using combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy (SIEB-VMAT). After RT, significant symptoms alleviation and durable tumor control were observed. CASE SUMMARY: At presentation, an 85-year-old male patient complained abdominal distention/pain, poor appetite, and swelling over bilateral lower limbs for 1 month. On physical examination, a jaundice pattern was noted. Laboratory studies showed impaired liver and renal function. Abdominal computed tomography (CT) revealed a 12.5-cm bulky tumor over the caudate lobe of the liver. Biopsy was done, and hepatocellular carcinoma (HCC) was reported histopathologically. As a result, AJCC stage IIIA (cT3aN0M0) and BCLC stage C were classified. Surgery, radiofrequency ablation (RFA), trans-catheter arterial chemoembolization (TACE), and sorafenib were not recommended because of his old age, central bulky tumor, and a bleeding tendency. Thus, RT with SIEB-VMAT technique was given alternatively. RT was delivered in 26 fractions, with dose gradience as follows: 39 Gy on the outer Plan Target Volume (PTV), 52 Gy in the middle PTV, and 57.2 Gy in the inner PTV. Unexpectedly, cyproheptadine (a newly recognized potential anti-HCC agent) was retrospectively found to be prescribed for alleviating skin itching and allergic rhinitis since the last 2 weeks of the RT course (2 mg by mouth Q12h for 24 months). After RT, significant symptoms alleviation and tumor volume reduction were observed for 32 months till multiple bone metastases. Before and after RT, a large tumor volume reduction rate of 88.7% was observed (from 608.4 c.c. to 68.7 c.c.). No severe treatment toxicity was noted during and after RT. The patient died due to aspiration pneumonia with septic shock at 4 months after bone metastases identified. CONCLUSIONS: SIEB-VMAT physically demonstrated double benefits of intratumor dose escalation and extra-tumor dose attenuation. Significant tumor regression and symptoms alleviation were observed in this elderly patient with unresectable bulky HCC. Further prospective randomized trials are encouraged to demarcate effective size of SIEB-VMAT with or without cyproheptadine. Wolters Kluwer Health 2016-08-26 /pmc/articles/PMC5400349/ /pubmed/27559982 http://dx.doi.org/10.1097/MD.0000000000004717 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 5700 Lin, Young-Hsiang Hung, Shih-Kai Chiou, Wen-Yen Lee, Moon-Sing Shen MD, Bing-Jie Chen, Liang-Cheng Liu, Dai-Wei Tsai, Wei-Ta Lin, Po-Hao Shih, Yi-Ting Hsu, Feng-Chun Tsai, Shiang-Jiun Chan, Michael W.Y. Lin, Hon-Yi Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title_full | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title_fullStr | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title_full_unstemmed | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title_short | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report |
title_sort | significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: a care-compliant case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400349/ https://www.ncbi.nlm.nih.gov/pubmed/27559982 http://dx.doi.org/10.1097/MD.0000000000004717 |
work_keys_str_mv | AT linyounghsiang significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT hungshihkai significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT chiouwenyen significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT leemoonsing significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT shenmdbingjie significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT chenliangcheng significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT liudaiwei significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT tsaiweita significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT linpohao significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT shihyiting significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT hsufengchun significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT tsaishiangjiun significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT chanmichaelwy significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport AT linhonyi significantsymptomsalleviationandtumorvolumereductionaftercombinedsimultaneouslyintegratedinnerescalatedboostandvolumetricmodulatedarcradiotherapyinapatientwithunresectablebulkyhepatocellularcarcinomaacarecompliantcasereport |